Vivanta Industries Ltd (541735)

Vivanta Industries announced the approval of its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. However, the filing extract only contains the cover outcome letter and omits the detailed financial result tables and Limited Review Report (Annexure-A). The company currently operates with a market cap of Rs 21 Cr and a low promoter holding of 10.6%. Investors will need to refer to the full financial statements to assess revenue and margin performance for the period.

• Board approved unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026
• Meeting commenced at 04:00 P.M. and concluded at 05:00 P.M. on November 05, 2026
• Financial figures and Annexure-A Limited Review Report omitted in the current filing document extract

Vivanta Industries Ltd has scheduled a meeting of its Board of Directors on Thursday, November 5, 2026. The board will consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, along with the Limited Review Report. The trading window for designated persons remains closed and will reopen 48 hours after the declaration of the financial results.

• Board meeting scheduled for November 5, 2026 at 04:00 P.M.
• Agenda to consider Q2 and H1 FY27 results ended September 30, 2026
• Trading window closed until 48 hours post results declaration

Vivanta Industries Limited has submitted a regulatory disclosure confirming the non-applicability of the Statement of Deviation or Variation under Regulation 32 of SEBI LODR Regulations. The company reported that it has not raised any funds via Public Issue, Rights Issue, or Preferential Issue. Consequently, no deviation reporting is required for the period. This is a standard compliance filing confirming no fresh equity dilution or issue proceeds utilization.

• Filing submitted under Regulation 32 of SEBI LODR Regulations on October 8, 2026
• Confirmed zero funds raised via Public Issue, Rights Issue, or Preferential Issue
• Statement of Deviation or Variation not applicable for the period
• Reference to SEBI Circular No. CIR/CFD/CMD1/162/2019 dated 24th December, 2019

Vivanta Industries announced the resignation of Mr. Devang Shah from his position as Company Secretary, Compliance Officer, and Key Managerial Personnel. The resignation is effective from the close of business hours on October 1, 2026. The departure is attributed to personal reasons and pursuing career opportunities outside the company, with no other material reasons cited. This administrative departure affects a micro-cap company with a market cap of Rs 21 Cr and FY26 revenue of Rs 250.1 Cr.

• Devang Shah stepped down as Company Secretary & Compliance Officer on October 1, 2026
• Cessation takes effect from the close of business hours on October 1, 2026
• Reason cited is pursuing career opportunities outside the company with no other material reasons

Vivanta Industries announced shareholder approval at its 13th AGM on September 30, 2026, to adopt a new set of Memorandum of Association (MOA) and Articles of Association (AOA). The amendments align the corporate charter with the Companies Act, 2013, replacing references from the erstwhile Companies Act, 1956. The main objects under Clause III (A) remain unchanged, with alterations primarily restructuring incidental objects and liability clauses to standard statutory formats.

• Shareholders approved adoption of new MOA and AOA at the 13th AGM held on September 30, 2026
• Existing Clause III (B) replaced with matters necessary for furtherance containing sub-clauses 1 to 99
• No changes made to Clause III (A) containing the core Main Objects (sub-clauses 1 to 3)
• Adoption aligns statutory charter from Companies Act 1956 to Companies Act 2013 Table-A and Table-F formats

Vivanta Industries has scheduled a Board of Directors meeting on September 2, 2026, to approve the Board's Report and Secretarial Audit Report for FY 2025-2026 and convene its 13th Annual General Meeting (AGM). The agenda also includes approving material Related Party Transactions for FY 2026-2027, revising borrowing limits under Section 180(1)(c), and approving loans/investments under Sections 185 and 186. Additionally, the Board will consider adopting updated Memorandum and Articles of Association under the Companies Act, 2013.

• Board meeting scheduled for September 2, 2026, at the company's registered office
• Approval of Board's Report, Secretarial Audit Report, and FY26 Financial Statements
• Proposal to revise borrowing authority under Section 180(1)(c) and approve loans under Sections 185 and 186
• Review and approval of material Related Party Transactions for FY 2026-2027
• Appointment of M/s. Jitendra Parmar & Associates as scrutinizer for the 13th AGM

Vivanta Industries Ltd has filed a statement of non-applicability regarding Regulation 32 of SEBI (LODR) Regulations. The company confirmed that it has not raised any funds through Public Issues, Rights Issues, Preferential Issues, or Qualified Institutions Placements (QIP) during the period. Consequently, there are no deviations or variations in fund utilization to report. This is a standard administrative filing required for regulatory compliance.

• Confirmed zero funds raised through Public, Rights, or Preferential Issues
• Statement of Deviation or Variation is not applicable as per SEBI Circular dated 24th December 2019
• Compliance filing submitted to BSE on August 1, 2026
• No change in capital structure reported through these specific fundraising routes

Vivanta Industries approved its unaudited financial results for the quarter ended June 30, 2026, during its board meeting on July 29, 2026. While specific Q1 figures were not detailed in the summary text, the company announced a new business collaboration with Qness Pharmaceuticals for manufacturing, branding, and marketing. This comes after a fiscal year (FY26) where the company achieved Rs 250 Cr in revenue but maintained a very thin PAT of Rs 1 Cr. The board also authorized opening a trading and demat account with Motilal Oswal, indicating active treasury or investment management.

• Approved standalone and consolidated financial results for the quarter ended June 30, 2026.
• Executed a business collaboration agreement with Qness Pharmaceuticals for pharma product supply and marketing.
• Company operates with a low promoter holding of 10.6% as of March 2026.
• Reported TTM revenue of Rs 250 Cr against a small market capitalization of only Rs 19 Cr.
• Debt levels remain significant at Rs 18 Cr, resulting in a Debt-to-Equity ratio of 1.00.

Vivanta Industries has rescheduled its board meeting from July 24 to July 29, 2026, citing heavy rainfall and adverse weather conditions. The board will meet to approve the unaudited financial results for the quarter ended June 30, 2026, and sign the audited statements for FY26. Additionally, the agenda includes a business collaboration agreement with Qness Pharmaceuticals for the manufacture and marketing of pharmaceutical products. This is significant as the company currently operates in civil construction with thin TTM margins of -0.8% and a low promoter holding of 10.6%.

• Board meeting rescheduled from July 24, 2026, to July 29, 2026.
• Agenda includes approval of financial results for the quarter ended June 30, 2026.
• Board to consider a business collaboration agreement with Qness Pharmaceuticals.
• Authorization of signatories for FY26 audited financial statements (year ended March 31, 2026).
• Company reports TTM revenue of ₹250 cr against a small market cap of ₹19 cr.